Last €13.54 EUR
Change Today +0.58 / 4.44%
Volume 0.0
I3F On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 3:19 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

infinity pharmaceuticals inc (I3F) Snapshot

Open
€13.17
Previous Close
€12.97
Day High
€13.80
Day Low
€13.17
52 Week High
12/22/14 - €14.69
52 Week Low
05/9/14 - €6.09
Market Cap
660.4M
Average Volume 10 Days
109.7
EPS TTM
--
Shares Outstanding
48.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INFINITY PHARMACEUTICALS INC (I3F)

infinity pharmaceuticals inc (I3F) Related Businessweek News

No Related Businessweek News Found

infinity pharmaceuticals inc (I3F) Details

Infinity Pharmaceuticals, Inc., a drug discovery and development company, focuses on discovering, developing, and delivering medicines to people with difficult-to-treat diseases. Its lead product candidate includes IPI-145, an oral inhibitor of Class I delta and gamma isoforms of phosphoinositide-3-kinase (PI3K) for the treatment of hematologic malignancies and inflammatory diseases. The company is conducting DUOTM, a randomized, monotherapy Phase 3 study of IPI-145 in patients with relapsed/refractory chronic lymphocytic leukemia; an ongoing Phase 1 dose-escalation study to evaluate the safety, pharmacokinetics, and clinical activity of IPI-145 in patients with advanced hematologic malignancies; a Phase 2 study to evaluate the efficacy, safety, and pharmacokinetics of IPI-145 in patients with rheumatoid arthritis; and a Phase 2a trial of IPI-145 in patients with mild allergic asthma, as well as completed a Phase 1 trial of IPI-145 in healthy adult subjects. It also develops IPI-443, an oral inhibitor of PI3K-delta and gamma; and IPI-940, an inhibitor of fatty acid amide hydrolase. The company has strategic collaboration with AbbVie Inc. to develop and commercialize duvelisib (IPI-145) in oncology. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

180 Employees
Last Reported Date: 02/25/14

infinity pharmaceuticals inc (I3F) Top Compensated Officers

Chairman of The Board, Chief Executive Office...
Total Annual Compensation: $552.0K
Chief Financial Officer, Chief Business Offic...
Total Annual Compensation: $378.8K
President of Research & Development
Total Annual Compensation: $465.8K
Chief Scientific Officer
Total Annual Compensation: $366.4K
Compensation as of Fiscal Year 2013.

infinity pharmaceuticals inc (I3F) Key Developments

Infinity Pharmaceuticals, Inc. Provides Financial Guidance for Year 2015; Anticipates to Report Top Line Data from Dynamo

Infinity Pharmaceuticals, Inc. provided financial guidance for year 2015. The company expects revenue for 2015 to range from $105 million to $125 million based on the anticipation of a $130 million milestone payment from AbbVie associated with the completion of enrollment of either DYNAMO or DUO in 2015. Net loss for 2015 to range from $190 million to $210 million. Infinity anticipates that it will report top line data from DYNAMO, a Phase 2 study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma (iNHL), in the second half of 2015 following the completion of patient enrollment in the first half of the year. Infinity also expects to complete enrollment of DUO, a Phase 3 study of duvelisib in patients with relapsed/refractory chronic lymphocytic leukemia (CLL), in the second half of 2015. During the year, Infinity expects three company-sponsored clinical studies of duvelisib to be initiated, including the first clinical study of duvelisib in combination with venetoclax (ABT-199). Duvelisib is an investigational oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma being developed jointly with AbbVie in oncology.

Infinity Reports Topline Results from Phase 2 Study of Duvelisib in Rheumatoid Arthritis

Infinity Pharmaceuticals, Inc. announced that ASPIRA, a Phase 2 study of duvelisib, an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, with background methotrexate in patients with moderate-to-severe rheumatoid arthritis (RA) did not meet its primary endpoint. The primary endpoint was the ACR20 response rate at 12 weeks, which is defined as the proportion of patients who achieve at least a 20% improvement in American College of Rheumatology (ACR) response criteria after 12 weeks of study treatment. Infinity will not proceed with any further clinical development of its PI3K inhibitors in rheumatoid arthritis. Infinity is continuing to focus on advancing duvelisib for the treatment of blood cancers and is conducting registration-focused studies of duvelisib in indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia, forms of blood cancer for which there are no cures. This Phase 2, double-blind, randomized, placebo-controlled study was designed to evaluate the efficacy, safety and pharmacokinetics of duvelisib dosed at either 0.5 mg, 1.0 mg or 5.0 mg twice daily (BID) for 12 weeks with background methotrexate compared to treatment with placebo plus methotrexate. The study evaluated 322 adults with active moderate-to-severe RA receiving a stable dose of methotrexate. The primary efficacy endpoint of the study was the ACR20 response rate at week 12. An effect of duvelisib compared to placebo was not observed on the primary endpoint at any of the three dose levels tested. The majority of side effects observed were Grade 1-2, reversible or clinically manageable, and no new safety signals associated with duvelisib therapy were identified. Infinity will continue to analyze the study results and expects to submit the data for publication in a peer-reviewed forum.

Infinity Pharmaceuticals, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 11:30 AM

Infinity Pharmaceuticals, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 11:30 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Adelene Q. Perkins, Chairman of the Board, Chief Executive Officer and President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
I3F:GR €13.54 EUR +0.58

I3F Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Array BioPharma Inc $7.16 USD -0.30
CTI BioPharma Corp $2.20 USD +0.03
Cytokinetics Inc $7.09 USD -0.36
Evotec AG €3.66 EUR -0.016
GlaxoSmithKline SAE £12.00 EGP 0.00
View Industry Companies
 

Industry Analysis

I3F

Industry Average

Valuation I3F Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.6x
Price/Book 3.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INFINITY PHARMACEUTICALS INC, please visit www.infi.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.